CagriSema vs Tesofensine
A side-by-side research comparison of CagriSema and Tesofensine across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | CagriSema | Tesofensine |
|---|---|---|
| Full name | CagriSema (Cagrilintide + Semaglutide) | Tesofensine (Triple Monoamine Reuptake Inhibitor) |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | Phase 3 Clinical Trial |
| Mechanism | Dual-pathway activation: cagrilintide mimics amylin to activate area postrema satiety centers, while semaglutide activates GLP-1 receptors for complementary appetite suppression. | Blocks presynaptic reuptake of noradrenaline, dopamine, and serotonin in the hypothalamus, enhancing satiety signaling, reducing food reward, and increasing thermogenesis. |
| Molecular weight | Combination product | 329.4 Da |
| Half-life | 7 days (both components) | 8-10 days |
| Bioavailability | High (SubQ) | High (oral ~93%) |
| Typical dose | Cagrilintide 2.4mg + Semaglutide 2.4mg | 0.25-0.5 mg |
| Frequency | Once weekly | Once daily |
| Route | Subcutaneous | Oral |
CagriSema reported benefits
- Enhanced weight loss vs monotherapy
- Dual appetite suppression
- Convenient single injection
- Improved metabolic parameters
- Potential 20-25% weight loss
Tesofensine reported benefits
- Significant appetite reduction
- Increased metabolic rate
- Improved satiety signaling
- 10-12% body weight loss
- Oral administration convenience
Related comparisons
Research and educational reference only. Not medical advice.